Improve thinking with brain stimulation
- Trial ID
- NCT06090682
- Official Title
- Effect and Mechanism of Deep Brain Stimulation and Transcranial Magnetic Stimulation on Parkinson's Disease With Cognitive Impairment
- Goal
- Improve thinking with brain stimulation
- Status
- RECRUITING
- Sponsor
- Tianjin Huanhu Hospital
- Study Type
- OBSERVATIONAL
- Enrollment
- 200 participants
- Conditions
- Parkinson Disease, Cognitive Impairment
- Interventions
- Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)
Plain-Language Summary
The goal is to understand whether and how deep brain stimulation and transcranial magnetic stimulation can improve thinking and the brain circuits behind cognitive decline in people with Parkinson's who have had the disease for several years. DBS implants electrodes in the subthalamic nucleus to modulate abnormal circuit activity that drives symptoms and can influence cognition, while TMS uses noninvasive magnetic pulses to boost targeted cortical networks; the study will track cognitive changes and the underlying brain mechanisms, including how these effects relate to levodopa response. They are enrolling up to 200 adults up to age 75 with Parkinson's for more than 5 years who show at least a 30% improvement with an acute levodopa dose and are candidates for STN DBS, excluding those with severe cognitive impairment, major psychiatric illness, atypical parkinsonism, or surgical contraindications.
Locations
- Tianjin Huanhu Hospital, Tianjin, Tianjin Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS). The goal is to understand whether and how deep brain stimulation and transcranial magnetic stimulation can improve thinking and the brain circuits behind cognitive decline in people with Parkinson's who have had the disease for several years. DBS implants electrodes in the subthalamic nucleus to modulate abnormal circuit activity that drives symptoms and can influence cognition, while TMS uses noninvasive magnetic pulses to boost targeted cortical networks; the study will track cognitive changes and the underlying brain mechanisms, including how these effects relate to levodopa response. They are enrolling up to 200 adults up to age 75 with Parkinson's for more than 5 years who show at least a 30% improvement with an acute levodopa dose and are candidates for STN DBS, excluding those with severe cognitive impairment, major psychiatric illness, atypical parkinsonism, or surgical contraindications.
- Who can participate?
- Participants must be 75 Years or younger.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.